Zobrazeno 1 - 10
of 150
pro vyhledávání: '"Qamar J, Khan"'
Autor:
Shane R. Stecklein, Bruce F. Kimler, Rachel Yoder, Kelsey Schwensen, Joshua M. Staley, Qamar J. Khan, Anne P. O’Dea, Lauren E. Nye, Manana Elia, Jaimie Heldstab, Trisha Home, Stephen Hyter, Kamilla Isakova, Harsh B. Pathak, Andrew K. Godwin, Priyanka Sharma
Publikováno v:
npj Breast Cancer, Vol 9, Iss 1, Pp 1-8 (2023)
Abstract Triple-negative breast cancer (TNBC) patients with residual disease (RD) after neoadjuvant systemic therapy (NAST) are at high risk for recurrence. Biomarkers to risk-stratify patients with RD could help individualize adjuvant therapy and in
Externí odkaz:
https://doaj.org/article/00318f24d99f4b07bfee5dde9a0b9a2e
Autor:
Julie E. Lang, Andres Forero-Torres, Douglas Yee, Christina Yau, Denise Wolf, John Park, Barbara A. Parker, A. Jo Chien, Anne M. Wallace, Rashmi Murthy, Kathy S. Albain, Erin D. Ellis, Heather Beckwith, Barbara B. Haley, Anthony D. Elias, Judy C. Boughey, Rachel L. Yung, Claudine Isaacs, Amy S. Clark, Hyo S. Han, Rita Nanda, Qamar J. Khan, Kristen K. Edmiston, Erica Stringer-Reasor, Elissa Price, Bonnie Joe, Minetta C. Liu, Lamorna Brown-Swigart, Emanuel F. Petricoin, Julia D. Wulfkuhle, Meredith Buxton, Julia L. Clennell, Ashish Sanil, Scott Berry, Smita M. Asare, Amy Wilson, Gillian L. Hirst, Ruby Singhrao, Adam L. Asare, Jeffrey B. Matthews, Michelle Melisko, Jane Perlmutter, Hope S. Rugo, W. Fraser Symmans, Laura J. van ‘t Veer, Nola M. Hylton, Angela M. DeMichele, Donald A. Berry, Laura J. Esserman
Publikováno v:
npj Breast Cancer, Vol 8, Iss 1, Pp 1-10 (2022)
Abstract HSP90 inhibitors destabilize oncoproteins associated with cell cycle, angiogenesis, RAS-MAPK activity, histone modification, kinases and growth factors. We evaluated the HSP90-inhibitor ganetespib in combination with standard chemotherapy in
Externí odkaz:
https://doaj.org/article/f1ec1969e2aa401dafdcc1102c26a20e
Autor:
Rachel Yoder, Bruce F. Kimler, Joshua M. Staley, Kelsey Schwensen, Yen Y. Wang, Karissa Finke, Anne O’Dea, Lauren Nye, Manana Elia, Gregory Crane, Richard McKittrick, Robert Pluenneke, Sheshadri Madhusudhana, Larry Beck, Anuj Shrestha, Larry Corum, Mark Marsico, Shane R. Stecklein, Andrew K. Godwin, Qamar J. Khan, Priyanka Sharma
Publikováno v:
npj Breast Cancer, Vol 8, Iss 1, Pp 1-7 (2022)
Abstract Triple-negative breast cancer (TNBC) is classically defined by estrogen receptor (ER) and progesterone receptor (PR) immunohistochemistry expression
Externí odkaz:
https://doaj.org/article/cff802109f0d4e06a3ba6f327f1d9180
Autor:
Douglas Yee, Claudine Isaacs, Denise M. Wolf, Christina Yau, Paul Haluska, Karthik V. Giridhar, Andres Forero-Torres, A. Jo Chien, Anne M. Wallace, Lajos Pusztai, Kathy S. Albain, Erin D. Ellis, Heather Beckwith, Barbara B. Haley, Anthony D. Elias, Judy C. Boughey, Kathleen Kemmer, Rachel L. Yung, Paula R. Pohlmann, Debu Tripathy, Amy S. Clark, Hyo S. Han, Rita Nanda, Qamar J. Khan, Kristen K. Edmiston, Emanuel F. Petricoin, Erica Stringer-Reasor, Carla I. Falkson, Melanie Majure, Rita A. Mukhtar, Teresa L. Helsten, Stacy L. Moulder, Patricia A. Robinson, Julia D. Wulfkuhle, Lamorna Brown-Swigart, Meredith Buxton, Julia L. Clennell, Melissa Paoloni, Ashish Sanil, Scott Berry, Smita M. Asare, Amy Wilson, Gillian L. Hirst, Ruby Singhrao, Adam L. Asare, Jeffrey B. Matthews, Nola M. Hylton, Angela DeMichele, Michelle Melisko, Jane Perlmutter, Hope S. Rugo, W. Fraser Symmans, Laura J. van‘t Veer, Donald A. Berry, Laura J. Esserman
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-8 (2021)
Abstract I-SPY2 is an adaptively randomized phase 2 clinical trial evaluating novel agents in combination with standard-of-care paclitaxel followed by doxorubicin and cyclophosphamide in the neoadjuvant treatment of breast cancer. Ganitumab is a mono
Externí odkaz:
https://doaj.org/article/784de0fabd374658a9d09088fa4a5ee8
Autor:
Cory Bivona, Kevin Li, Priyanka Sharma, Jianghua He, Grace Martin, Andrew K Godwin, Anthony Rooney, Stephen Williamson, Gary Doolittle, Weijing Sun, Bruce F Kimler, Anne P O'Dea, Lauren E Nye, Joseph P McGuirk, Ziyan Pessetto, Lisa Haney, Nicole Balmaceda, Laura Mitchell, Karissa Finke, Maggie Nelson, Dinesh Pal Mudaranthakam, Natalie Streeter, Stephanie Lafaver, Jaimie Heldstab, Qamar J Khan
Publikováno v:
Cancer Research. 82:P4-10
Background: Infection with SARS-CoV-2 has led to a global pandemic and has significantly impacted the care of cancer patients. Breast cancer patients receiving active systemic therapy need protection against COVID19 but the efficacy of vaccines in th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2bffe47d2aba08b99634963be56dc78f
https://doi.org/10.1158/1538-7445.sabcs21-p4-10-03
https://doi.org/10.1158/1538-7445.sabcs21-p4-10-03
Autor:
Andrew K. Godwin, Qamar J. Khan, Bruce F. Kimler, Gregory A. Reed, Milind A. Phadnis, Stephen K. Williamson, Stephanie LaFaver, Jaimie Heldstab, Karissa Finke, Kelsey Schwensen, Rachel Yoder, Yen Y. Wang, Jilliann A. De Jong, Jecinta Scott, Sharon Lewis, Manana Elia, Shane R. Stecklein, Marc Hoffmann, Harsh B. Pathak, Ingrid Mayer, Lauren Nye, Anne O'Dea, Vandana G. Abramson, Priyanka Sharma
Supplementary text
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01abe936b9f7b7cf0046b9baf3d20f36
https://doi.org/10.1158/1078-0432.22481640.v1
https://doi.org/10.1158/1078-0432.22481640.v1
Autor:
Andrew K. Godwin, Qamar J. Khan, Bruce F. Kimler, Gregory A. Reed, Milind A. Phadnis, Stephen K. Williamson, Stephanie LaFaver, Jaimie Heldstab, Karissa Finke, Kelsey Schwensen, Rachel Yoder, Yen Y. Wang, Jilliann A. De Jong, Jecinta Scott, Sharon Lewis, Manana Elia, Shane R. Stecklein, Marc Hoffmann, Harsh B. Pathak, Ingrid Mayer, Lauren Nye, Anne O'Dea, Vandana G. Abramson, Priyanka Sharma
Purpose:PIK3CA mutations are common in breast cancer and promote tumor progression and treatment resistance. We conducted a phase I/II trial of alpelisib (α-specific PI3K inhibitor) plus nab-paclitaxel in patients with HER2-negative metastatic breas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a5663202857f8528f331d69cee18ca0d
https://doi.org/10.1158/1078-0432.c.6530748
https://doi.org/10.1158/1078-0432.c.6530748
Autor:
Miguel Martín, Andrew K. Godwin, Bruce F. Kimler, Roy A. Jensen, Jaimie Heldstab, Anne P. O’Dea, Amanda L. Amin, Jamie L. Wagner, Joshua V. Mammen, Jennifer R. Klemp, Yen Y. Wang, Carolyn Lehn, Charles M. Perou, Iván Márquez-Rodas, Denisse Bretel Morales, Hugo Fuentes-Rivera, Javier Cortés, Ricardo González del Val, María Isabel Palomero, Beatriz Pelaez-Lorenzo, Tatiana Massarrah, Milagros González-Rivera, María del Monte-Millán, Antoni C. Picornell, Agustí Barnadas, Yolanda Jerez-Gilarranz, Fernando Moreno, Aleix Prat, Henry L. Gómez, Qamar J. Khan, José Angel García-Saenz, Sara López-Tarruella, Priyanka Sharma
Purpose:Prognostic value of pathologic complete response (pCR) and extent of pathologic response attained with anthracycline-free platinum plus taxane neoadjuvant chemotherapy (NAC) in triple-negative breast cancer (TNBC) is unknown. We report recurr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b0a1a1ee8be5e76e560e64a45c6977d
https://doi.org/10.1158/1078-0432.c.6527297.v1
https://doi.org/10.1158/1078-0432.c.6527297.v1
Autor:
Miguel Martín, Andrew K. Godwin, Bruce F. Kimler, Roy A. Jensen, Jaimie Heldstab, Anne P. O’Dea, Amanda L. Amin, Jamie L. Wagner, Joshua V. Mammen, Jennifer R. Klemp, Yen Y. Wang, Carolyn Lehn, Charles M. Perou, Iván Márquez-Rodas, Denisse Bretel Morales, Hugo Fuentes-Rivera, Javier Cortés, Ricardo González del Val, María Isabel Palomero, Beatriz Pelaez-Lorenzo, Tatiana Massarrah, Milagros González-Rivera, María del Monte-Millán, Antoni C. Picornell, Agustí Barnadas, Yolanda Jerez-Gilarranz, Fernando Moreno, Aleix Prat, Henry L. Gómez, Qamar J. Khan, José Angel García-Saenz, Sara López-Tarruella, Priyanka Sharma
Pathological response to carboplatin plus docetaxel by germline BRCA status
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0767bda7352f9a9520ddbf3d324bdcc9
https://doi.org/10.1158/1078-0432.22469603
https://doi.org/10.1158/1078-0432.22469603
Autor:
Miguel Martin, Qamar J. Khan, Bruce F. Kimler, Roy A. Jensen, Andrew K. Godwin, Jaimie Heldstab, Carol J. Fabian, Amanda L. Amin, Jennifer R. Klemp, Marilee K. McGinness, Joshua M.V. Mammen, Jamie L. Wagner, Charles M. Perou, Iván Márquez-Rodas, Denisse Bretel Morales, Hugo Fuentes Rivera, Javier Cortes, Ricardo González del Val, María Isabel Palomero, Beatriz Pelaez-Lorenzo, Tatiana Massarrah, Milagros Gonzalez-Rivera, Maria del Monte-Millán, Antoni C. Picornell, Augusti Barnadas, Yolanda Jerez-Gilarranz, Fernando Moreno, Aleix Prat, Henry L. Gómez, Carol S. Connor, Claire Ward, Jose Angel García-Saenz, Sara López-Tarruella, Priyanka Sharma
Purpose: Recent studies demonstrate that addition of neoadjuvant (NA) carboplatin to anthracycline/taxane chemotherapy improves pathologic complete response (pCR) in triple-negative breast cancer (TNBC). Effectiveness of anthracycline-free platinum c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93a15be7bafdd234b05a5858647d4025
https://doi.org/10.1158/1078-0432.c.6525104
https://doi.org/10.1158/1078-0432.c.6525104